Operates a chain of in-vitro fertilisation (IVF) and women-health centres across India using a hub-and-spoke model, with 7 hubs and 28 spokes spread across 9 states as of FY26. Revenue comes from three streams: IVF treatment (64%), hospital services (31%), and pharmacy sales (4%). The business charges patients for fertility procedures, with average revenue per patient of Rs 2,97,998 and a reported 58% clinical pregnancy success rate on first IVF attempt. It differentiates using AI tools SiD (sperm assessment) and ERICA (embryo evaluation), developed with UK-based IVF 2.0, which it is rolling out into new centres. The largest cost lines are other operating expenses at 24.0% of revenue and employee costs at 7.7%, while materials cost is reported at 0% of revenue, consistent with a service-led model. FY26 consolidated revenue was Rs 104.36 crore with an EBITDA margin of 36.6%, down from 40.48% in FY25 as the company invested in expansion and AI deployment. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. IVF Treatment (64%), Hospital Services (31%), Pharmacy (4%). Asset-light, service-led IVF and women-health chain
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 104 |
| EBITDA (ex other income) | 38 |
| margin % | 36.1 |
| Owners' profit | 24 |
| EPS, as reported (₹) | 3.92 |
| ROE % · ROCE % | 16.1 · 23.1 |
| Debt / equity (x) | 0.15 |
| Cash from operations | 7 |
| Capex | (2) |
| ₹ crore | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 25 | 30 | 19 |
| Profit before tax | 5 | 10 | 2 |
| Net profit | 4 | 8 | 2 |
| EPS (₹) | 0.59 | 1.34 | 0.25 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Post-dispatch newspaper ad for 11th AGM notice and e-voting info | compliance | minimal | — | — |
| 3 Sept 2026 · Gaudium IVF sets Sep 28 AGM, FY26 annual report link shared with shareholders | compliance | minimal | — | — |
| 3 Sept 2026 · Gaudium IVF submits FY26 Annual Report; revenue up 47.6%, PAT up 27.7% | results | high | — | — |
| 3 Sept 2026 · 11th AGM on Sep 28, 2026 to approve director pay hike and auditor appointment | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Gaudium IVF informs about newspaper publication of 11th AGM notice | compliance | minimal | — | — |
| 19 Aug 2026 · Gaudium IVF Q1 FY27 earnings call transcript filed | investor communications | medium | — | — |
| 14 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 14 Aug 2026 · Revised Q1 FY27 investor presentation adds expense details | investor communications | medium | — | — |
| 13 Aug 2026 · Investor Presentation filed with the Exchange | investor communications | medium | — | — |
| 13 Aug 2026 · Monitoring Agency Report on Rs. 90 crore IPO proceeds, Q1 FY27 | compliance | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
